Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea
· Delayed Price · Currency is KRW 3,165.00
-95.00 (-2.91%)
At close: Apr 28, 2026
Vivozon Pharmaceutical Revenue
In the year 2025, Vivozon Pharmaceutical had annual revenue of 59.34B KRW, down -32.26%. Vivozon Pharmaceutical had revenue of 16.20B in the quarter ending December 31, 2025, a decrease of -30.33%.
Revenue
59.34B
Revenue Growth
-32.26%
P/S Ratio
3.21
Revenue / Employee
193.30M
Employees
307
Market Cap
190.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.34B | -28.26B | -32.26% |
| Dec 31, 2024 | 87.60B | 16.28B | 22.83% |
| Dec 31, 2023 | 71.32B | 19.75B | 38.31% |
| Dec 31, 2022 | 51.56B | -6.00B | -10.42% |
| Dec 31, 2021 | 57.56B | 13.97B | 32.04% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| High Tech Pharm | 70.18B |
| OPTUS Pharmaceutical | 87.16B |
| Organoidsciences | 2.41B |
| Kyung Dong Pharmaceutical | 196.27B |
| PHARMARESEARCH BIO | 178.19M |
| GREEN CROSS WellBeing | 164.68B |
| DongKoo Bio & Pharma | 242.69B |
| NOVAREX | 404.26B |